Subjects: TDS, FVT
Ocugen to Present at the Oppenheimer 28th Annual Healthcare Conference
MALVERN, Pa., March 15, 2018 /PRNewswire/ -- Ocugen, Inc., a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular diseases, today announced that it will present at the Oppenheimer & Co. 28th Annual Healthcare Conference, held March 20-21, 2018, in New York City.
Shankar Munsunuri, Ph.D., Chairman, CEO and Co-Founder of Ocugen will highlight Ocugen's industry-leading ophthalmology pipeline, which includes small molecules, highly targeted biologics, and a novel gene therapy platform. Ocugen anticipates entering pivotal clinical trials in 2018 for its two lead programs in ocular graft versus host disease and chronic dry eye disease.
Presentation Details:
Date: Tuesday, March 20, 2018
Time: 10:00 AM (Eastern Time)
Location: The Westin New York Grand Central, Track 3 Room
About Ocugen, Inc.
Ocugen, Inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. The Company's lead programs in ocular graft versus host disease (OCU300) and chronic dry eye disease (OCU310) are expected to enter pivotal clinical trials in 2018. OCU300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. Ocugen is also developing novel biologic therapies for retinitis pigmentosa (OCU100) and wet AMD (OCU200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (OCU400). For more information, please visit www.ocugen.com.
Contact:
Ocugen, Inc.
Kelly Morello
[email protected]
+1 484-328-4698
SOURCE Ocugen, Inc.
These press releases may also interest you
|
News published on and distributed by:
